Clinical Trial Update: Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC [Phase 2]

View source ↗

Summary

Phase 2 study evaluating durvalumab with tremelimumab, with or without platinum-based chemotherapy, in patients with metastatic non-small cell lung cancer (incl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Lung Cancer Metastatic | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-02-09